The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 03, 2015

Filed:

Feb. 03, 2006
Applicants:

Ralph A. Heasley, Webster Grove, MO (US);

Keith A. Moore, Loveland, OH (US);

Jeffrey S. Greiwe, Ft. Thomas, KY (US);

John W. Facemire, Douglasville, GA (US);

Jason D. Modest, Minneapolis, MN (US);

Inventors:

Ralph A. Heasley, Webster Grove, MO (US);

Keith A. Moore, Loveland, OH (US);

Jeffrey S. Greiwe, Ft. Thomas, KY (US);

John W. Facemire, Douglasville, GA (US);

Jason D. Modest, Minneapolis, MN (US);

Assignee:

Ferring B.V., Hoofddorp, NL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/22 (2006.01); A61K 9/20 (2006.01); A61K 31/195 (2006.01);
U.S. Cl.
CPC ...
A61K 9/2054 (2013.01); A61K 9/2027 (2013.01); A61K 31/195 (2013.01);
Abstract

Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.


Find Patent Forward Citations

Loading…